Effect of Teriparatide on Fracture Healing in Patients With Incomplete Atypical Femur Fractures
Model scores of the 29,894 trials active now.
Model score 14% for any early termination, 6% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 14% of the time (741 trials).
Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.
How it ended
Completed on 2022-12-31, after 2013-07-31 start.
The score above never used this outcome: finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.
Termination over time, as the model saw it at the start
Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2022-12-31. The rest of the way to 100% is still running.
From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.
What moved the score
-
Wording of the registration (title, summary, criteria) (raises risk) · Wording
Phrases that raised it: cancertherapymelanomasecondaryprior
Phrases that lowered it: participantsplacebocontrolledblindmyeloma -
Minimum age: 30 (lowers risk) · Who can join
-
Accepts healthy volunteers: No (raises risk) · Who can join
-
Sponsor's past termination rate: 9.8% (raises risk) · Sponsor's track record
-
Phase: 3 (lowers risk) · Design
-
Maximum age: 100 (lowers risk) · Who can join
-
Sponsor type: academic or other (raises risk) · Sponsor's track record
-
Drug's FAERS reports with a death: 9.4% (lowers risk) · Drug's FDA history
-
Trials the sponsor started in the prior 2 years: 79 (lowers risk) · Sponsor's track record
-
Collaborators: 2 (lowers risk) · Design
-
Blinding: triple (raises risk) · Design
-
Disease area, cancer: No (lowers risk) · Disease area
-
Primary purpose: treatment (raises risk) · Design
-
Design: parallel (raises risk) · Design
-
Sponsor's past trials: 173 (lowers risk) · Sponsor's track record
-
Keywords listed: 0 (lowers risk) · Design
-
Drug's FAERS reports before start: 38359 (lowers risk) · Drug's FDA history
Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.
The trial
Design
- Phase
- 3 (typical: 2)
- Number of arms
- 2
- Allocation
- randomized
- Design
- parallel
- Primary purpose
- treatment
- Blinding
- triple (typical: none)
- Has a data monitoring committee
- No (typical: 56% yes)
- Responsible party
- sponsor
- Collaborators
- 2 (typical: 0)
- Keywords listed
- 0 (typical: 1)
Who can join
- Minimum age
- 30 (typical: 18)
- Maximum age
- 100 (typical: 71)
- Sex
- all
- Accepts healthy volunteers
- No (typical: 9% yes)
Sponsor's track record
- Sponsor type
- academic or other
- Sponsor's past trials
- 173 (typical: 32)
- Sponsor's past termination rate
- 9.8% (typical: 9.9%)
- Trials the sponsor started in the prior 2 years
- 79 (typical: 19)
Drug's FDA history
- Drugs with FDA adverse-event history
- 1
- Drug has FAERS history
- Yes (typical: 64% yes)
- Drug's FAERS reports before start
- 38359 (typical: 2148)
- Drug's FAERS reports in the prior 12 months
- 4712 (typical: 412.5)
- Drug's FAERS reports marked serious
- 75.0% (typical: 85.6%)
- Drug's FAERS reports with a death
- 9.4% (typical: 15.9%)
Disease area and drugs
- Disease areas
- none of the 14 tracked areas
- Drugs matched to FDA substances
- teriparatide
Typical values are among the trials active now. Sponsor and drug history are counted only up to this trial's start date.
Similar finished trials
- Second Study of the Effect of Teriparatide on Hip Fracture Healing NCT01473602 · started 2012 · scored riskier than 43% of active trials completed
- Effect of Teriparatide on Hip Fracture Healing NCT01473589 · started 2012 · scored riskier than 42% of active trials completed
- The Effect of Teriparatide on Bone Union in Unstable Intertrochanteric Fracture Patients Treated With PFNA NCT03133195 · started 2017 · scored riskier than 41% of active trials completed
- PTH(1-34) and Pelvic Fracture Healing - a Randomized Controlled Trial NCT02972424 · started 2017 · scored riskier than 64% of active trials completed
- Forteo for the Treatment of Unexplained Osteoporosis in Premenopausal Women NCT00697463 · started 2008 · scored riskier than 21% of active trials completed
Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.